News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeritas Presents Data Showing Greater Reductions In A1c And Insulin Dose With V-Go Wearable Insulin Delivery Device Compared To Insulin Pen Devices In Patients With Type 2 Diabetes



2/17/2017 8:18:31 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Data presented at The 10th International Conference on Advanced Technologies & Treatments for Diabetes

BRIDGEWATER, New Jersey, February 16, 2017 --- Valeritas Holdings, Inc. (OTCQB: VLRX) today announced data showing greater reductions in A1c and insulin dose in patients with type 2 diabetes who used V-Go® Wearable Insulin Delivery device compared to patients using insulin pen devices. The data were presented as an E-Poster at The 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), February 15 to 18, in Paris, France.

The study was a retrospective analysis based on electronic medical records from a multicenter diabetes system in the United States. Patients with A1c levels greater than seven percent and transitioning from basal only to basal and mealtime insulin were included in the analysis. The primary endpoint was to evaluate the difference in A1c change between V-Go and insulin pens.

One hundred seven patients (50 V-Go and 57 insulin pens) were evaluated. Baseline parameters were similar between the two groups. By 27 weeks, the changes in A1c levels were -1.96% with V-Go and -1.23% with insulin pens for a treatment difference at 27 weeks of 0.73; p=0.011, favoring V-Go. In addition, insulin dose and needle sticks were less with V-Go compared to insulin pens (56 vs 77 units/day; p<0.001 and 1.0 vs 3.6 sticks/day; p<0.001, respectively).

“This study is of particular relevance to European physicians and their patients as insulin pens are the primary delivery system for insulin for patients with type 2 diabetes in Europe,” said John Timberlake, President and Chief Executive Officer of Valeritas. “While we remain focused on continuing to grow our customer base and prudently increase our commercial footprint in the U.S., we welcome opportunities such as ATTP to present our compelling clinical data to European audiences as we continue to explore potential commercial partners to distribute V-Go in the region.”

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

Read at BioSpace.com


comments powered by Disqus
 
 
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES